Volume 10 Issue 8, August 2010

The tumour suppressor ASPP2 is involved in the regulation of cell polarity.

Four recent papers extend the MLL interactome.

Amoebae and neutrophils can swim, and the mechanisms by which they do so share similarities with cell movement across a solid surface.

A new family of microRNAs induces epithelial–mesenchymal transition and metastases formation by inhibiting DICER.

In nematodes, HIF1 can suppress p53-mediated apoptosis in response to DNA damage through a systemic pathway involving a secreted neuronal tyrosinase.

Two papers reveal more about MYC addiction and regulation in cellular transformation.

Having an extra copy of an anti-angiogenic gene and several endothelial cell-specific genes on chromosome 21, which is present in triplicate in individuals with Down's syndrome, is sufficient to slow tumour growth by preventing angiogenesis.

A new inhibitor of the androgen receptor for use in the treatment of prostate cancer.

Pseudogenes regulate the expression of their corresponding gene by functioning as miRNA decoys.

Three papers identify a new role for RB1 in regulating sister chromatid cohesion, which suppresses tumorigenesis by preventing chromosome instability

Numerous oncoproteins depend on the molecular chaperone heat shock protein 90 (HSP90). However, the optimal use of HSP90-targeted therapeutics will depend on understanding the complexity of HSP90 regulation and the degree to which the chaperone participates in both neoplastic and normal cellular physiology.

High-risk human papillomaviruses are considered the causative agents of most cervical cancers. The modifications by the human papillomavirus E6 and E7 oncoproteins of cell cycle progression, telomere maintenance, apoptosis and chromosomal stability and their fundamental role in transformation are discussed in this Review.

The inhibitor of apoptosis (IAP) proteins were first investigated because of their capacity to inhibit programmed cell death in response to a number of physiological stimuli. Their disruption is also evident in many types of human cancer. As small pharmacological inhibitors of IAPs enter clinical trials, this Review examines what we now know about the function of a subset of family members — cIAP1, cIAP2 and XIAP.

The ANGPT–TIE2 pathway is important for angiogenesis, lymphangiogenesis and inflammation, and therefore has important roles in cancer. Given the context-dependent and opposing effects of the ANGPTs, how do we target this pathway?

This Opinion article discusses how aberrant vascular remodelling might lead to tumour hypoxia. What controls this process, and could this be reversed — or normalized — by anti-angiogenic therapies?